Format

Send to

Choose Destination
J Bone Miner Res. 2019 Mar 28. doi: 10.1002/jbmr.3722. [Epub ahead of print]

Relationship Between Bone Mineral Density T-score and Nonvertebral Fracture Risk Over 10 Years of Denosumab Treatment.

Author information

1
Geneva University Hospital, Geneva, Switzerland.
2
Amgen Inc., Thousand Oaks, CA, USA.
3
Laval University and CHU de Québec Research Centre, Quebec City, QC, Canada.
4
Columbia University, NY, USA.
5
Krakow Medical Center, Krakow, Poland.
6
Center for Clinical and Basic Research - Brasil, Rio de Janeiro, Brazil.
7
Universitat Autònoma de Barcelona, Barcelona, Spain.
8
University of Liège, Liège, Belgium.
9
New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM, USA.

Abstract

Although treat-to-target strategies are being discussed in osteoporosis, there is little evidence of what the target should be to maximally reduce fracture risk. We investigated the relationship between total hip BMD T-score and the incidence of nonvertebral fracture in women who received up to 10 years of continued denosumab therapy in the FREEDOM trial (3 years) and its long-term Extension (up to 7 years). We report the percentages of women who achieved a range of T-scores at the total hip or femoral neck over 10 years of denosumab treatment (1,343 women completed 10 years of treatment). The incidence of nonvertebral fractures was lower with higher total hip T-score. This relationship plateaued at a T-score between -2.0 and -1.5 and was independent of age and prevalent vertebral fractures, similar to observations in treatment-naïve subjects. Reaching a specific T-score during denosumab treatment was dependent on the baseline T-score, with higher T-scores at baseline more likely to result in higher T-scores at each time point during the study. Our findings highlight the importance of follow-up BMD measurements in patients receiving denosumab therapy, since BMD remains a robust indicator of fracture risk. These data support the notion of a specific T-score threshold as a practical target for therapy in osteoporosis. This article is protected by copyright. All rights reserved.

KEYWORDS:

DXA; antiresorptives; fracture risk assessment; osteoporosis; treat to target.

PMID:
30919997
DOI:
10.1002/jbmr.3722

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center